In the future, co-targeting CAIX/XII activity in combination with ferroptosis inducers, such as inhibitors of GPX4, have the potential to achieve substantial in-roads in treating hypoxic tumours, especially those exhibiting chemo- and radio-resistance. The gene discussed is CA9; the disease is neoplasm.